ButoBeiwe is a company that has identified multiple novel New Chemical Entities (NCEs) that are anti-inflammatory molecules for age-related disease and longevity. Its assets and goals are listed on our website, butobeiwe.com.

Buto focuses on NCE small-molecule Shc Inhibitors, ShcI's, that suppress age-related inflammatory indications: Idiopathic Pulmonary Fibrosis (IPF), Graft-vs.-Host Disease (GvHD), and Alzheimer's disease (AD).

Beiwe focuses on small-molecule mTOR inhibitors, that unlike rapamycin are totally mTORC1-specific, to suppress age-related inflammation and extend longevity.